Organogenesis HoldingsORGO
ORGO
About: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Employees: 869
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,200% more call options, than puts
Call options by funds: $156K | Put options by funds: $12K
3.72% more ownership
Funds ownership: 50.88% [Q1] → 54.6% (+3.72%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
9% less capital invested
Capital invested by funds: $279M [Q1] → $254M (-$25.3M) [Q2]
18% less funds holding
Funds holding: 136 [Q1] → 112 (-24) [Q2]
40% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 48
51% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 41
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
87%
upside
Avg. target
$9
87%
upside
High target
$9
87%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Ross Osborn | 87%upside $9 | Overweight Maintained | 8 Aug 2025 |
Financial journalist opinion
Based on 3 articles about ORGO published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants David C. Francisco - Chief Financial Officer Gary S.
Neutral
The Motley Fool
2 weeks ago
ORGO Sales Drop 23%
ORGO Sales Drop 23%
Neutral
GlobeNewsWire
2 weeks ago
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
1 month ago
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th.
Neutral
GlobeNewsWire
1 month ago
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation
CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services' (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based products (CTPs) under the CY 2026 Physician Fee Schedule and urges CMS to establish 2026 payment rates based on clinical value and relative cost.
Positive
Seeking Alpha
2 months ago
Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario
ORGO's main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. They have a Phase 3 trial on ReNu knee-osteoarthritis with data anticipated by September 2025. Its potential BLA filing could eventually unlock the injectable OA market. CMS skin-substitute LCD was postponed to January 2026. This regulatory standard will require more robust evidence for insurance reimbursements.
Neutral
Seeking Alpha
3 months ago
Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief Financial Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Operator Welcome, ladies and gentlemen, to the First Quarter 2025 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and its subsequently filed quarterly reports.
Negative
Zacks Investment Research
3 months ago
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.04. This compares to loss of $0.02 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
4 months ago
Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness
Organogenesis recommends CMS also implement an integrated coverage and payment policy Organogenesis recommends CMS also implement an integrated coverage and payment policy
Charts implemented using Lightweight Charts™